PMID- 32070623
OWN - NLM
STAT- MEDLINE
DCOM- 20201007
LR  - 20201007
IS  - 1873-3573 (Electronic)
IS  - 0039-9140 (Linking)
VI  - 211
DP  - 2020 May 1
TI  - Use of a newly-developed portable capillary electrophoresis analyser to detect 
      drugs of abuse in oral fluid: A case study.
PG  - 120662
LID - S0039-9140(19)31295-0 [pii]
LID - 10.1016/j.talanta.2019.120662 [doi]
AB  - The aim of the current study was to develop and validate an analytical method to 
      determine whether drugs of abuse (DOA) were present in oral fluid (OF) using a 
      newly-developed, portable capillary electrophoresis (CE) instrument coupled to a 
      deep ultra-violet fluorescence detector (FD). The performance of this portable 
      CE-FD DOA analyser was tested at the Weekend Festival Baltic (Parnu, Estonia) 
      between 2016 and 2018 as well as on the roadside OF samples collected by the 
      police. The study reported 128 analysed cases in which persons were allegedly 
      found to have been under the influence of DOA. The samples were analysed for 
      amphetamine (AMP), methamphetamine (METH), 3,4-methylenedioxy-methamphetamine 
      (MDMA), 3,4-methylenedioxyamphetamine (MDA), 
      3,4-methylenedioxy-N-ethylamphetamine (MDEA), cocaine (COC) and cocaethylene 
      (COET). Subsequent toxicological reports revealed that 26% cases were negative, 
      and 74% were positive. The most frequently detected and quantified DOA was MDMA 
      (68 cases, 62%). A comparative study was conducted to validate the accuracy of 
      using the CE-FD DOA analyser versus classic high-performance liquid 
      chromatography coupled to mass spectrometry (HPLC-ESI-MS). Diagnostic statistics 
      for CE-FD DOA were also evaluated and were higher than 99.5%. In addition, all 
      zeta-scores were lower than 2 when both methods were compared, showing that the 
      CE-FD analyser can be implemented as a reliable, sensitive and convenient tool 
      for roadside and workplace testing for DOA.
CI  - Copyright (c) 2019 Elsevier B.V. All rights reserved.
FAU - Saar-Reismaa, Piret
AU  - Saar-Reismaa P
AD  - Department of Chemistry and Biotechnology, School of Science, Tallinn University 
      of Technology, Akadeemia Tee 15, 12618, Tallinn, Estonia.
FAU - Brilla, Chelsa-Ann
AU  - Brilla CA
AD  - Department of Chemistry and Biotechnology, School of Science, Tallinn University 
      of Technology, Akadeemia Tee 15, 12618, Tallinn, Estonia.
FAU - Leiman, Kristiina
AU  - Leiman K
AD  - Department of Chemistry and Biotechnology, School of Science, Tallinn University 
      of Technology, Akadeemia Tee 15, 12618, Tallinn, Estonia.
FAU - Kaljurand, Mihkel
AU  - Kaljurand M
AD  - Department of Chemistry and Biotechnology, School of Science, Tallinn University 
      of Technology, Akadeemia Tee 15, 12618, Tallinn, Estonia.
FAU - Vaher, Merike
AU  - Vaher M
AD  - Department of Chemistry and Biotechnology, School of Science, Tallinn University 
      of Technology, Akadeemia Tee 15, 12618, Tallinn, Estonia.
FAU - Kulp, Maria
AU  - Kulp M
AD  - Department of Chemistry and Biotechnology, School of Science, Tallinn University 
      of Technology, Akadeemia Tee 15, 12618, Tallinn, Estonia.
FAU - Mazina-Sinkar, Jekaterina
AU  - Mazina-Sinkar J
AD  - Department of Chemistry and Biotechnology, School of Science, Tallinn University 
      of Technology, Akadeemia Tee 15, 12618, Tallinn, Estonia. Electronic address: 
      jekaterina.mazina@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20191220
PL  - Netherlands
TA  - Talanta
JT  - Talanta
JID - 2984816R
RN  - 0 (Amphetamines)
RN  - 0 (Illicit Drugs)
RN  - FJO3071W5Y (cocaethylene)
RN  - I5Y540LHVR (Cocaine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Amphetamines/*analysis
MH  - Cocaine/*analogs & derivatives/analysis
MH  - Female
MH  - Fluorescence
MH  - Humans
MH  - Illicit Drugs/*analysis
MH  - Male
MH  - Middle Aged
MH  - Saliva/*chemistry
MH  - Substance Abuse Detection/*methods
MH  - Young Adult
OTO - NOTNLM
OT  - Capillary electrophoresis
OT  - Drug analyser
OT  - Drugs of abuse
OT  - Fluorescence
OT  - On-site testing
OT  - Oral fluid
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/02/20 06:00
MHDA- 2020/10/08 06:00
CRDT- 2020/02/20 06:00
PHST- 2019/09/14 00:00 [received]
PHST- 2019/12/18 00:00 [revised]
PHST- 2019/12/19 00:00 [accepted]
PHST- 2020/02/20 06:00 [entrez]
PHST- 2020/02/20 06:00 [pubmed]
PHST- 2020/10/08 06:00 [medline]
AID - S0039-9140(19)31295-0 [pii]
AID - 10.1016/j.talanta.2019.120662 [doi]
PST - ppublish
SO  - Talanta. 2020 May 1;211:120662. doi: 10.1016/j.talanta.2019.120662. Epub 2019 Dec 
      20.